Shares of China’s Shanghai Henlius Biotech will debut on the Hong Kong stock exchange later this week after the company collected $410m in an IPO that was priced at the bottom end of the targeted range.
Shanghai Henlius Biotech, a subsidiary of billionaire Guo Guangchang’s Fosun group, will make its trading debut this week on the Hong Kong stock exchange after raising $410m in an initial public offering that marked the first sizeable offering to test investor appetite since the eruption of the city’s ongoing street protests.
Henlius, which developed the first “made-in-China” biosimilar to be approved by China, focuses on creating follow-on versions of blockbuster biologics...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
